UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Amendment No. 1
Under the Securities Exchange Act of 1934
SciClone Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
80862K104
- --------------------------------------------------------------------------------
(CUSIP Number)
November 18, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
-2-
- --------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Aptafin SpA
- --------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
- --------------------------------------------------------------------------------
3. SEC Use Only
- --------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Italy
- --------------------------------------------------------------------------------
5. Sole Voting Power
360,500
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 909,500
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 360,500
-----------------------------------------------------
8. Shared Dispositive Power
909,500
- --------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,270,000
- --------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions) / /
- --------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
5.10%
- --------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
<PAGE>
-3-
- --------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Sigma-Tau Finanziaria SpA
- --------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
- --------------------------------------------------------------------------------
3. SEC Use Only
- --------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Italy
- --------------------------------------------------------------------------------
5. Sole Voting Power
909,500
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 0
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 909,500
-----------------------------------------------------
8. Shared Dispositive Power
0
- --------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
909,500
- --------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes
Certain Shares (See Instructions) / /
- --------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
3.65%
- --------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
<PAGE>
-4-
Item 1(a). Name of Issuer:
SciClone Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
901 Mariner's Island Boulevard, Suite 315, San Mateo, CA 94404
Item 2(a). Name of Person Filing:
This statement is filed on behalf of each of the following persons
(collectively, the "Reporting Persons")
(i) Aptafin SpA ("Aptafin"),
(2) Sigma-Tau Finanziaria SpA ("Sigma-Tau")
Item 2(b). Address of Principal Business Office:
(1)
Aptafin
Via Santissimi Pietro e Paolo, 30
00144 Rome
Italy
(2)
Sigma-Tau
Via Sudafrica, 20
00144 Rome
Italy
Item 2(c). Citizenship:
(1) Aptafin is an Italian corporation.
(2) Sigma-Tau is an Italian corporation.
Item 2(d). Title of Class of Securities:
Common Stock, no par value (the "Shares")
Item 2(e). CUSIP Number:
80862K104
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person is a:
This Item 3 is not applicable
<PAGE>
-5-
Item 4. Ownership:
Aptafin
(a) Amount beneficially owned: 1,270,000
(b) Percent of class: 5.10%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct
the vote: 360,500
(ii) shared power to vote or to direct
the vote: 909,500
(iii) sole power to dispose or to direct
the disposition of: 360,500
(iv) shared power to dispose or to direct
the disposition of: 909,500
Sigma-Tau
(a) Amount beneficially owned: 909,500
(b) Percent of class: 3.65%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct
the vote: 909,500 (1)
(ii) shared power to vote or to direct
the vote: 0
(iii) sole power to dispose or to direct
the disposition of: 909,500 (1)
(iv) shared power to dispose or to direct
the disposition of: 0
---------
(1): 445,000 of the Shares held by Sigma Tau are restricted shares and are
subject to certain limitations on resale.
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company:
Not Applicable
Item 8. Identification and Classification of Members of the Group:
Not Applicable
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
<PAGE>
-6-
By signing below, I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect.
<PAGE>
-7-
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: November 17, 1999
APTAFIN SPA
By: /s/ Piero Belletti
-------------------------------------
Name: Piero Belletti
Title: Managing Director
Dated: November 17, 1999
SIGMA TAU FINANZIARIA SPA
By: /s/ Paolo Cavazza
-------------------------------------
Name: Paolo Cavazza
Title: Vice President and
Managing Director
<PAGE>
-8-
EXHIBIT INDEX
Page No.
A. Joint Filing Agreement dated November 17, 1999 by and
among Aptafin SpA and Sigma Tau Finanziaria
SpA................................................... 9
<PAGE>
-9-
EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G with
respect to the Common Stock of SciClone Pharmaceuticals, Inc. dated as of
November 18, 1999 is, and any amendments thereto (including amendments on each
of us pursuant to and in accordance with the provisions of Rule 13d-1(f) under
the Securities Exchange Act of 1934).
Dated: November 17, 1999
APTAFIN SPA
By: /s/ Piero Belletti
------------------------------------
Name: Piero Belletti
Title: Managing Director
SIGMA TAU FINANZIARIA SPA
Dated: November 17, 1999
By: /s/ Paolo Cavazza
------------------------------------
Name: Paolo Cavazza
Title: Vice President and
Managing Director
